FOXO4-DRI: The Senolytic Peptide Explained

Senescent cells have stopped dividing but refuse to die. They build up with age, and in mice, removing them delays several features of ageing. In 2017 a team in Rotterdam reported a peptide that makes them die on cue. They called it FOXO4-DRI, and it became one of the most talked-about molecules in ageing research.

This guide explains what FOXO4-DRI is, how it was designed, what the mouse studies showed, what has not been shown, and what to check before ordering it in Canada.

What senescent cells are

When a cell is badly damaged, it has two main ways out: it can self-destruct through apoptosis, or it can enter senescence, a permanent stop to dividing. Senescence protects against cancer in the short term, but senescent cells linger, and they release inflammatory signals that can disrupt the tissue around them. They accumulate with age. Earlier mouse work showed that genetically clearing them can delay some features of ageing, which raised an obvious question: could a drug clear them instead?

Drugs that do that are called senolytics. Most early candidates were small molecules. FOXO4-DRI was designed from the biology of senescence itself.

How FOXO4-DRI works

De Keizer’s group found that senescent cells rely on a protein called FOXO4 to survive. In the nucleus, FOXO4 binds p53, the protein that would otherwise push a damaged cell toward apoptosis, and holds it in check. Interrupt that interaction, they reasoned, and the senescent cell should finally die.

“DRI” stands for D-retro-inverso. The peptide is built from D-amino acids, the mirror images of the L-amino acids that make up natural proteins, arranged in reverse order. That trick keeps the overall shape of the side chains similar to the natural sequence while making the peptide far more resistant to the enzymes that normally break peptides down. A cell-penetrating segment lets it get inside cells.

What the mouse studies showed

In cell culture, the peptide selectively drove senescent cells into apoptosis by excluding p53 from the nucleus. In mice, under conditions where it was well tolerated, it countered the toxicity of the chemotherapy drug doxorubicin, which induces senescence. In fast-ageing mice carrying the XpdTTD/TTD mutation, and in naturally aged mice, it restored fitness, fur density and kidney function.

The authors’ central claim was that clearing senescent cells could restore tissue function even after health had already declined, not just prevent decline. That is what made the paper stand out.

What has not been shown

Related ageing research peptides

FOXO4-DRI targets one biological process linked to ageing. Others in our catalogue target different ones: Epitalon in telomere research, and MOTS-c and SS-31 in mitochondrial research. Our anti-aging peptides guide maps them all.

FOXO4-DRIThe senolytic D-retro-inverso peptideView product and COA EpitalonTelomerase research tetrapeptideView product and COA MOTS-cMitochondrial-derived peptideView product and COA SS-31Cardiolipin-binding tetrapeptideView product and COA

Sourcing FOXO4-DRI in Canada

FOXO4-DRI raises a testing question most peptides don’t. Before ordering, check that:

• The mass matches the expected sequence. See HPLC vs mass spectrometry.
• You know what was not tested. D- and L-amino acids have identical masses, and standard purity methods generally cannot tell an all-D peptide from its all-L version. If chirality matters to your work, ask whether it was checked.
• The COA matches your lot. How to read a certificate of analysis walks through it.
• Storage is cold, dry and dark. See our peptide storage guide.

Frequently asked questions